• About Us
    • Our Team
    • Our Work
    • In The News
  • Resources
    • Curated Research Library
    • Popular Articles
    • Legal Beagle Archive
    • The Education Program
    • VCS Vet Research Program
  • Directory of Practitioners
  • Get Involved
    • Become A Sponsor
    • Join Email List
  • Contact
  • SHOP NOW
    • VCS APPAREL
    • PET & PARENT JEWELRY
  • DONATE
  • Members Dashboard
Veterinary Cannabis SocietyVeterinary Cannabis Society
  • About Us
    • Our Team
    • Our Work
    • In The News
  • Resources
    • Curated Research Library
    • Popular Articles
    • Legal Beagle Archive
    • The Education Program
    • VCS Vet Research Program
  • Directory of Practitioners
  • Get Involved
    • Become A Sponsor
    • Join Email List
  • Contact
  • SHOP NOW
    • VCS APPAREL
    • PET & PARENT JEWELRY
  • DONATE
  • Members Dashboard

Effects of alprazolam and cannabinoid-related compounds in an animal model of panic attack

Home Effects of alprazolam and cannabinoid-related compounds in an animal model of panic attack

Curated Research Library

  • Back to Curated Research Library

Effects of alprazolam and cannabinoid-related compounds in an animal model of panic attack

  • By: Batista, L. A., Haibara, A. S., Moreira, F. A., & Schenberg
  • Published On: 15 January, 2017
  • Publication: Sciencedirect.com
  • Tags: general, Human medicine
  • Category: Behavior

Selective stimulation of carotid chemoreceptors by intravenous infusion of low doses of potassium cyanide (KCN) produces short-lasting escape responses that have been proposed as a model of panic attack. In turn, preclinical studies suggest that facilitation of the endocannabinoid system attenuate panic-like responses. Here, we compared the effects of cannabinoid-related compounds to those of alprazolam, a clinically effective panicolytic, on the duration of the escape reaction induced by intravenous infusion of KCN (80 μg) in rats. Alprazolam (1, 2, 4 mg/kg) decreased escape duration at doses that did not alter basal locomotor activity. URB597 (0.1, 0.3, 1 mg/kg; inhibitor of anandamide hydrolysis), WIN55,212-2 (0.1, 0.3, 1 mg/kg; synthetic cannabinoid), arachidonoyl-serotonin (1, 2.5, 5 mg/kg; dual TRPV1 and anandamide hydrolysis inhibitor), and cannabidiol (5, 10, 20, 40 mg/kg; a phytocannabinoid) did not decrease escape duration. Alprazolam also prevented the increase in arterial pressure evoked by KCN, while bradycardia was unchanged. This study reinforces the validity of the KCN-evoked escape as a model of panic attack. However, it does not support a role for the endocannabinoid system in this behavioral response. These results might have implications for the screening of novel treatments for panic disorder.

Click Here to Access Article
  • Back to Curated Research Library
Search

Our Mission is to create lasting solutions that ensure the safe use of cannabis in pets through education, advocacy, and promoting product standards.

Our Vision is an educated and empowered global veterinary medical cannabis community.

  • About Us
  • Our Work
  • Get Involved
  • Contact Us
  • Donate

Email:
Click here to email us

Florida Mailing Address
7901 4th St. North, Suite 4404
St. Petersburg, FL 33702

Veterinary Cannabis Society is a nonprofit, 501(c)(3) organization in the United States. Tax ID #85-0986090

Veterinary Cannabis Society does not endorse any specific products.

© 2025 · Veterinary Cannabis Society

  • Terms of Use
  • Privacy Policy
  • State Notices
  • Contact